TABLE 3.

Effectiveness of subjects in combination with existing drugs.

Name	Anti-LC drugs	Effect of combination	References
Fisetin	Erlotinib	enhance the cytotoxic effect of the drug	Tabasum and Singh (2019)
Matrine	5-fluorouracil	matrine increased the sensitivity of lung CSCs to 5-FU and inhibited the accumulation of CCND1 in tumor tissues induced by 5-FU.	Li et al. (2020b)
TP	Paclitaxel	reversing EMT and impairing tumor growth in paclitaxel-resistant LUAD cells	Tian et al. (2021)
EPBS	-	modulation of Wnt pathway protein activity in EGFR overexpressing and EGFR depleted cancer cells with potential for anti-TKI resistance	Kim et al. (2022a)
Epibrassinolide	Etoposide	the combination index showed synergism between epibrassinolide and etoposide and between epibrassinolide and doxorubicin. Reversing resistance to two chemotherapeutics	Sadava and Kane (2017)
	Doxorubicin
FV-429	Paclitaxel	remodeling of fatty acid metabolism in hypoxia-induced paclitaxel-resistant NSCLC through inactivation of the Wnt pathway and increasing sensitivity to paclitaxel	Guo et al. (2021)
Miao	Cisplatin	simultaneous treatment can significantly enhance the effect of DDP on LC cells. It can synergistically regulate the proliferation and apoptosis of lung cancer cells	Li et al. (2020a)
OYSL	Cisplatin	treatment with QYSL broth alone was milder compared to DDP, however, the combination of QYSL broth and chemotherapy demonstrated enhanced anti-tumor effects compared to treatment administered alone	Tong et al. (2018)
FYLM	Osimertinib	sensitizing EGFR Del19/T790M/C797S mutant NSCLC cells to osimertinib	Shi et al. (2023)
FYN	Osimertinib	synergistic effect against cell proliferation and migration. Inhibit drug resistance	Sang et al. (2022)